FATE Fate Therapeutics Inc.

-0.18  -1%
Previous Close 16.14
Open 16.09
Price To Book 6.46
Market Cap 1037910912
Shares 65,032,012
Volume 303,429
Short Ratio
Av. Daily Volume 661,749

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data released at SITC November 10, 2017.
Acute myelogenous leukemia (AML)
Phase 2 efficacy part of trial has been initiated - noted September 18, 2017.
ProTmune - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
Phase 1 trial initiated February 2018.
Solid tumors
Phase 1 dosing commenced February 2019.
Soild tumors

Latest News

  1. Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors
  2. Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT
  3. Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript
  4. Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
  5. Fate Therapeutics, Inc. to Host Earnings Call
  6. Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results
  7. Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
  8. Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  9. Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings
  10. Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  11. Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
  12. Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day
  13. Fate Therapeutics stock up 11% after FDA clears IND application
  14. Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell
  15. Why Fate Therapeutics, Inc.’s (NASDAQ:FATE) CEO Pay Matters To You
  16. Vanda Pharmaceuticals: Recent Developments and Analyst Ratings
  17. Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up
  18. Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
  19. Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
  20. Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%